4 syllables: da, sa, ti, nib. Stress on sa.
/dəˈsætɪnɪb/
Say it backDasatinib is a targeted cancer therapy, a kinase inhibitor used to treat certain leukemias and other cancers. It inhibits the BCR-ABL, SRC family, and other tyrosine kinases, disrupting malignant cell signaling and growth. In medical contexts, it’s prescribed under close supervision, with emphasis on dosage, side effects, and monitoring.
- You often misplace the stress, saying da-SAT-i-nib or das-a-TI-nib. Fix: place primary stress on the third syllable: das-a-TEE-nib. - You shorten the long E in -ti- or blend it into -nib; keep /tiː/ clearly. Fix: hold the /iː/ for a beat before the final /nɪb/. - Final consonant release: avoid ending with a clipped /b/; ensure a crisp release: /b/ is voiced and audible. Practice slow, then natural pace. - Accent drift: in quick speech, you may slur vowels; rehearse with syllable-timed pacing to maintain even syllable length.
"The patient was started on dasatinib after detecting the BCR-ABL fusion gene."
"Researchers evaluated dasatinib’s effectiveness in combating acute lymphoblastic leukemia."
"Clinicians monitor for myelosuppression and pleural effusion as they adjust dasatinib dosage."
- Pronounce as das-a-TEE-nib, with primary stress on the third syllable: /ˌdæsəˈtiːnɪb/. Break it into four syllables: das-a-ti-nib. The middle “ti” is a long E as in tea. The vowel sounds are short for da- and sa-, then a clear long E in -ti-, ending with -nib. Practice by saying: das-a-TEE-nib, slowly, then speed up. Visualize: /ˌdæsəˈtiːnɪb/.
Common errors: 1) Stressing the first syllable (AR- as in DÁ-), instead of the third syllable; 2) Slurring the middle -ti- into -ti-nib- as a quick -ti- n-; 3) Mispronouncing the final -nib as -neeb or -nib-silent. Correction: place primary stress on the third syllable: das-a-TEE-nib; keep /tiː/ as a long E; end clearly with /nɪb/. Practice the sequence slowly: das-a-TI-neeb, then das-a-TEE-nib.
US/UK/AU share /ˌdæsəˈtiːnɪb/ with main stress on the third syllable. Differences are vowel quality: US rhotics are more pronounced in surrounding vowels; UK and AU are non-rhotic but still produce the same stressed syllables with slightly shorter vowel durations in some speakers. AU may exhibit a vowel height that’s a touch more centralized in fast speech. Overall, the core syllable rhythm remains the same.
Dasatinib starts with a cluster of consonants and contains a long E in the stressed syllable, which can be tricky if you’re not familiar with long-vowel marks in scientific terms. The sequence -ti- emphasizes a long /iː/ sound, and the final -b must be clearly released. Non-native speakers often misplace the stress or flatten the long vowel. Practice by isolating /tiː/ with a held E, and ensure the final /b/ is released.
Attention to the long /iː/ in the stressed syllable is crucial: /ˌdæsəˈtiːnɪb/. Keep the syllables evenly spaced and avoid a rapid diphthong in -ti-. Build the rhythm by tapping the syllables: das-a-TEE-nib. Another tip: practice with minimal pairs where the stressed syllable changes meaning—though not common in this word, it trains your ear for fixed stress patterns in scientific terms.
🗣️ Voice search tip: These questions are optimized for voice search. Try asking your voice assistant any of these questions about "dasatinib"!
- US: Rhotic influence is subtle; keep /dæsə/ clear, then /ˈtiːnɪb/ with crisp /tiː/ and final /nɪb/. - UK: Slightly shorter vowel duration in /tiː/ and crisper /nɪb/; keep non-rhoticity in surrounding vowels; - AU: Similar to US with slightly more centralized /ə/ in the first two syllables; maintain the long /iː/ in /tiː/; ensure final /b/ is released. - IPA references: US /ˌdæsəˈtiːnɪb/, UK /ˌdæsəˈtiːnɪb/, AU /ˌdæsəˈtiːnɪb/.
Dasatinib is a modern, proprietary small-molecule drug whose name is constructed to reflect its pharmacological target and chemical class. The prefix “dasa-” in pharmacological nomenclature often suggests a medicinal agent, while the suffix “-tinib” follows the common naming convention for tyrosine kinase inhibitors (TKIs) that end in -nib or -tinib, derived from the word kinase and the -nib ending indicating inhibition. The root is built to imply a potent, selective inhibitor for certain kinases involved in cancer cell signaling. The term appears in biomedical literature and clinical practice in the early 2000s as a part of the expansion of TKIs, with first official approvals around 2006–2008 in oncology. Etymological development tracks from pharmacological naming conventions rather than a natural-language origin, combining Greek/Latin roots for medicinal naming with modern chemical nomenclature. The first known usage occurs in drug development documentation and clinical trial reports as researchers identified dasatinib’s activity against BCR-ABL and SRC kinases, establishing its role as a targeted therapy. Over time, the word dasatinib has become a technical term in hematology and oncology, with usage concentrated in clinical settings and pharmacology literature rather than everyday language. It has no historical roots in common lexicon beyond its integration into drug names and regulatory databases.
💡 Etymology tip: Understanding word origins can help you remember pronunciation patterns and recognize related words in the same language family.
Help others use "dasatinib" correctly by contributing grammar tips, common mistakes, and context guidance.
💡 These words have similar meanings to "dasatinib" and can often be used interchangeably.
🔄 These words have opposite meanings to "dasatinib" and show contrast in usage.
📚 Vocabulary tip: Learning synonyms and antonyms helps you understand nuanced differences in meaning and improves your word choice in speaking and writing.
Words that rhyme with "dasatinib"
-nib sounds
Practice with these rhyming pairs to improve your pronunciation consistency:
🎵 Rhyme tip: Practicing with rhyming words helps you master similar sound patterns and improves your overall pronunciation accuracy.
